Indivior Pharmaceuticals (INDV) Gross Profit (2024 - 2026)

Indivior Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at $277.0 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 25.34% year-over-year to $277.0 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 12.55% increase from a year earlier, with the FY2025 full-year figure at $994.0 million, up 3.87% from the prior year.
• Gross Profit fell to $277.0 million in Q1 2026 per INDV's latest filing, from $292.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $292.0 million in Q4 2025 and bottomed at $220.0 million in Q2 2024.
• The 3-year median for Gross Profit is $246.0 million (2024), against an average of $247.4 million.
• Across the five-year window, Gross Profit retreated 10.16% in 2025 and grew 25.34% in 2026, its largest moves.
• Year by year, Gross Profit stood at $250.0 million in 2024, then grew by 16.8% to $292.0 million in 2025, then decreased by 5.14% to $277.0 million in 2026.
• Per Business Quant, the three latest INDV Gross Profit figures stand at $277.0 million (Q1 2026), $292.0 million (Q4 2025), and $230.0 million (Q3 2025).